title: Antiangiogenic activity of 2-formyl-8-hydroxy-quinolinium chloride.
abstract: Tumour growth is closely related to the development of new blood vessels to supply oxygen and nutrients to cancer cells. Without the neovascular formation, tumour volumes cannot increase and undergo metastasis. Antiangiogenesis is one of the most promising approaches for antitumour therapy. The exploration of new antiangiogenic agents would be helpful in antitumour therapy. Quinoline is an aromatic nitrogen compound characterized by a double-ring structure which exhibits a benzene ring fused to pyridine at two adjacent carbon atoms. The high stability of quinoline makes it preferable in a variety of therapeutic and pharmaceutical applications, including antitumour treatment. This work is to examine the potential antiangiogenic activity of the synthetic compound 2-Formyl-8-hydroxy-quinolinium chloride. We found that 2-Formyl-8-hydroxy-quinolinium chloride could inhibit the growth of human umbilical vein endothelial cells in vitro. Using the diethylnitrosamine-induced hepatocarcinogenesis model, 2-Formyl-8-hydroxy-quinolinium chloride showed strong antiangiogenic activity. Furthermore, 2-Formyl-8-hydroxy-quinolinium chloride could inhibit the growth of large Hep3B xenografted tumour from the nude mice. We assume that 2-Formyl-8-hydroxy-quinolinium chloride could be a potential antiangiogenic and antitumour agent and it is worthwhile to further study its underlying working mechanism.
authors.affiliation: State Key Laboratory of Chirosciences, Department of Applied Biology and Chemical Technology, The Hong Kong Polytechnic University, Hong Kong, China.
authors.forename: K-H
authors.initials: KH
authors.lastname: Lam
authors.affiliation: School of Biomedical Sciences, The Chinese University of Hong Kong, China.
authors.forename: K K-H
authors.initials: KK
authors.lastname: Lee
authors.affiliation: School of Biomedical Sciences, The Chinese University of Hong Kong, China.
authors.forename: S H-L
authors.initials: SH
authors.lastname: Kok
authors.affiliation: Department of Medicine and Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong, China.
authors.forename: R S-M
authors.initials: RS
authors.lastname: Wong
authors.affiliation: Department of Medicine and Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong, China.
authors.forename: F-Y
authors.initials: FY
authors.lastname: Lau
authors.affiliation: Faculty of Health Sciences, University of Macau, Macau, China.
authors.forename: G Y-M
authors.initials: GY
authors.lastname: Cheng
authors.affiliation: Department of Chemistry, Hong Kong Baptist University, Hong Kong, China.
authors.forename: W-Y
authors.initials: WY
authors.lastname: Wong
authors.affiliation: Department of Medicine and Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong, China.
authors.forename: S-W
authors.initials: SW
authors.lastname: Tong
authors.affiliation: Department of Medicine and Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong, China.
authors.forename: K-W
authors.initials: KW
authors.lastname: Chan
authors.affiliation: Clinical Division, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, China.
authors.forename: R Y-K
authors.initials: RY
authors.lastname: Chan
authors.affiliation: State Key Laboratory of Chirosciences, Department of Applied Biology and Chemical Technology, The Hong Kong Polytechnic University, Hong Kong, China. Electronic address: bccotang@polyu.edu.hk.
authors.forename: J C-O
authors.initials: JC
authors.lastname: Tang
authors.affiliation: State Key Laboratory of Chirosciences, Department of Applied Biology and Chemical Technology, The Hong Kong Polytechnic University, Hong Kong, China.
authors.forename: C-H
authors.initials: CH
authors.lastname: Cheng
authors.affiliation: Clinical Division, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, China.
authors.forename: D K-P
authors.initials: DK
authors.lastname: Hau
authors.affiliation: Clinical Division, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, China. Electronic address: bzxiang@hkbu.edu.hk.
authors.forename: Z-X
authors.initials: ZX
authors.lastname: Bian
authors.affiliation: Department of Life Sciences and Biotechnology, University of Ferrara, Ferrara, Italy. Electronic address: gam@unife.it.
authors.forename: R
authors.initials: R
authors.lastname: Gambari
authors.affiliation: State Key Laboratory of Chirosciences, Department of Applied Biology and Chemical Technology, The Hong Kong Polytechnic University, Hong Kong, China; Department of Medicine and Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong, China; Clinical Division, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, China. Electronic address: chchui@hkbu.edu.hk.
authors.forename: C-H
authors.initials: CH
authors.lastname: Chui
mesh_terms: D020533:Angiogenesis Inhibitors / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use; D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D063646:Carcinogenesis / Q000473:pathology; D006528:Carcinoma, Hepatocellular / Q000098:blood supply / Q000188:drug therapy / Q000473:pathology; D016923:Cell Death / Q000187:drug effects; D049109:Cell Proliferation / Q000187:drug effects; D004052:Diethylnitrosamine; D061307:Human Umbilical Vein Endothelial Cells / Q000187:drug effects; D006801:Humans; D006912:Hydroxyquinolines / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use; D008113:Liver Neoplasms / Q000098:blood supply / Q000188:drug therapy / Q000473:pathology; D008810:Mice, Inbred C57BL; D008819:Mice, Nude; D011806:Quinolinium Compounds / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use; D047368:Tumor Burden / Q000187:drug effects; D023041:Xenograft Model Antitumor Assays
chemical_list: C000613725:2-formyl-8-hydroxyquinolinium; D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D006912:Hydroxyquinolines; D011806:Quinolinium Compounds; D004052:Diethylnitrosamine
keywords: 2-Formyl-8-hydroxy-quinolinium chloride; Antiangiogenesis; Antitumour; Diethylnitrosamine-induced hepatocarcinogenesis; Hepatoma xenograft